Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 9.12
NRCIB's Cash-to-Debt is ranked higher than
59% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. NRCIB: 9.12 )
Ranked among companies with meaningful Cash-to-Debt only.
NRCIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 3.27 Max: No Debt
Current: 9.12
Equity-to-Asset 0.69
NRCIB's Equity-to-Asset is ranked higher than
65% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NRCIB: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
NRCIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.64 Max: 0.8
Current: 0.69
0.21
0.8
Interest Coverage 163.34
NRCIB's Interest Coverage is ranked higher than
56% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. NRCIB: 163.34 )
Ranked among companies with meaningful Interest Coverage only.
NRCIB' s Interest Coverage Range Over the Past 10 Years
Min: 23.53  Med: 52.24 Max: 164.19
Current: 163.34
23.53
164.19
Piotroski F-Score: 8
Altman Z-Score: 11.50
Beneish M-Score: -2.55
WACC vs ROIC
1.92%
38.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 28.52
NRCIB's Operating Margin % is ranked higher than
95% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NRCIB: 28.52 )
Ranked among companies with meaningful Operating Margin % only.
NRCIB' s Operating Margin % Range Over the Past 10 Years
Min: 21.86  Med: 25.29 Max: 28.63
Current: 28.52
21.86
28.63
Net Margin % 18.45
NRCIB's Net Margin % is ranked higher than
93% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NRCIB: 18.45 )
Ranked among companies with meaningful Net Margin % only.
NRCIB' s Net Margin % Range Over the Past 10 Years
Min: 13.41  Med: 15.99 Max: 18.76
Current: 18.45
13.41
18.76
ROE % 25.61
NRCIB's ROE % is ranked higher than
90% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. NRCIB: 25.61 )
Ranked among companies with meaningful ROE % only.
NRCIB' s ROE % Range Over the Past 10 Years
Min: 17.31  Med: 21.98 Max: 26.84
Current: 25.61
17.31
26.84
ROA % 16.74
NRCIB's ROA % is ranked higher than
93% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NRCIB: 16.74 )
Ranked among companies with meaningful ROA % only.
NRCIB' s ROA % Range Over the Past 10 Years
Min: 10.1  Med: 12.72 Max: 16.5
Current: 16.74
10.1
16.5
ROC (Joel Greenblatt) % 271.66
NRCIB's ROC (Joel Greenblatt) % is ranked higher than
98% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NRCIB: 271.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NRCIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 94.26  Med: 154.01 Max: 275.14
Current: 271.66
94.26
275.14
3-Year Revenue Growth Rate 5.50
NRCIB's 3-Year Revenue Growth Rate is ranked higher than
55% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NRCIB: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NRCIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.3 Max: 19.8
Current: 5.5
0
19.8
3-Year EBITDA Growth Rate 7.50
NRCIB's 3-Year EBITDA Growth Rate is ranked higher than
57% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NRCIB: 7.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NRCIB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.6 Max: 44.1
Current: 7.5
0
44.1
3-Year EPS without NRI Growth Rate 9.70
NRCIB's 3-Year EPS without NRI Growth Rate is ranked higher than
63% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. NRCIB: 9.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NRCIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.1 Max: 58.7
Current: 9.7
0
58.7
GuruFocus has detected 3 Warning Signs with National Research Corp $NRCIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NRCIB's 10-Y Financials

Financials (Next Earnings Date: 2017-05-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

NRCIB Guru Trades in

NRCIB Guru Trades in

NRCIB Guru Trades in

Q4 2016

NRCIB Guru Trades in Q4 2016

Paul Tudor Jones 5,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NRCIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621399    SIC: 8099
Compare:NAS:NEO, OTCPK:EPLYF, NAS:VIVO, OTCPK:BMLIF, NYSE:ARA, NAS:HSKA, NAS:QDEL, NAS:PACB, NAS:NTRA, NYSE:NVTA, NAS:LNTH, NAS:NVDQ, NAS:BEAT, NYSE:ENZ, NAS:OXFD, NAS:ONVO, NAS:SRDX, NAS:ALOG, NAS:RDNT, NAS:MGEN » details
Headquarter Location:USA
National Research Corp provides analytics and insights that improves measurement and improvement of the patient and employee experience. Its subscription-based solutions provide actionable information and analysis to healthcare organizations.

National Research Corp is a Wisconsin corporation, founded in 1981. The Company implements surveys and performs analysis that recognize a provider's strengths and problem areas, and then uses the data to design specific, measurable improvement strategies. The Company's portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company partners with clients across the continuum of healthcare services. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The two segments, organized by geographic area, are National Research Corporation (United States) and National Research Corporation Canada, which each offer a portfolio of solutions to address specific market needs around growth, retention, engagement and thought leadership for healthcare organizations. The Company's primary competitors among such specialty firms include Press Ganey. The Company competes with traditional market research firms which are providers of survey-based, general market research and firms which provide services or products that complement healthcare performance assessments such as healthcare software or information systems.

Top Ranked Articles about National Research Corp

National Research Corporation to Broadcast its 2017 First Quarter Conference Call Live on the Internet
Backtesting Feature Identifies Top-Performing Strategies New feature insight: high dividend yields offer strong portfolio returns
GuruFocus launched the new Backtesting feature within the All-in-One Guru Screener on June 20, allowing users to model an investing strategy’s performance relative to the Standard & Poor’s 500 index, one of the most commonly used benchmarks. Read more...
National Research Corporation Declares Quarterly Dividend
LINCOLN, NE--(Marketwired - May 12, 2016) - National Research Corporation (NASDAQ: NRCIA) (NASDAQ: NRCIB) today announced that its Board of Directors has declared a quarterly cash dividend of $0.08 (eight cents) per Class A share and $.48 (forty-eight cents) per Class B share payable Friday, July 15, 2016, to shareholders of record as of the close of business on Thursday, June 30, 2016. For more than 35 years, National Research Corporation has been at the forefront of patient-centered care, helping healthcare providers measure and improve quality and services through analytics that offer a rich understanding of customers' experiences, preferences, risks and behaviors across the healthcare continuum.

Contact:
Kevin R. Karas


Chief Financial Officer


402-475-2525




Read more...
Report: Georgia Nursing Homes Praised by Consumers
LINCOLN, NE--(Marketwired - May 10, 2016) - Ninety percent of families surveyed rated the Georgia nursing home providing care to their loved one as either excellent or good according to a 2015 study conducted by National Research Corporation, an organization that analyzes healthcare performance data in the United States and Canada. In addition, 87 percent of residents gave high marks to the care they received at the skilled nursing care center where they lived. National Research is making this announcement during National Nursing Home Week -- celebrated May 8-14 -- to recognize providers in Georgia and their dedication to pursuing excellence. Georgia holds the unique distinction of having the longest-running record of regular satisfaction measurement for residents, families, and employees of nursing homes in the nation-13 years. Measureable improvements have been documented in virtually all of the clinical, workforce, and satisfaction indices that comprise the initiative."Being able to maintain such a high level of performance over the past 13 years is a true testament to the quality of care being provided in Georgia nursing homes," said Rich Kortum, Director of Strategic Partnerships for National Research Corporation. "We are honored to work with such an outstanding organization, and we applaud GHCA for their continued focus on quality improvement.""The Georgia Health Care Association is profoundly grateful for our members and their unwavering commitment to advancing quality of care and service," said Tony Marshall, President and CEO for the Georgia Health Care Association. "We are very proud of the resident and family's recognition of our commitment, which is validated through the satisfaction survey process year after year."More than 95 percent of Georgia's nursing homes participate in the state's quality value-based purchasing program. Georgia utilizes satisfaction surveys and workforce data in combination with clinical outcomes results from National Research and the Centers for Medicare and Medicaid Services (CMS) as the basis for awarding small additional payments to facilities that meet pre-determined performance targets. A point scoring system calculates these data to determine eligibility for quarterly incentives. The program plays a small but important role in Medicaid reimbursement, applying a positive influence with minimal additional expense to the Medicaid program. This innovative model is often recognized by other states as a guide to developing new strategies for performance measurement. To find a skilled nursing care facility near you visit the Resources page of www.GHCA.info or www.Facebook.com/GHCA.info.About National Research CorporationFor more than 30 years, National Corporation (NASDAQ: NRCIA) (NASDAQ: NRCIB) has been at the forefront of patient-centered care. Today's the company's focus on empowering customer-centric healthcare across the continuum, which extends patient-centered care to incorporate families, communities, employees, senior housing residents and other stakeholders.Currently recognized by Modern Healthcare as one of the largest patient satisfaction measurement firms in the U.S., National Research is dedicated to representing the true voice of patients and other healthcare stakeholders. This integration of cross-continuum metrics and analytics uncovers insights for effective performance improvement, quality measurement, care transitions and many other factors that impact population health management.For more information, call 800-388-4264, write to [email protected], or visit www.nationalresearch.com.About Georgia Health Care AssociationFounded in 1953, the Georgia Health Care Association is a not-for-profit organization representing long-term and post-acute care providers located throughout the state of Georgia. The association is dedicated to enhancing the ability of providers to provide competent and compassionate care and advocates for quality care and services for frail, elderly and disabled Georgians. GHCA's more than 350 members serve more than 58,000 individuals annually. For more information visit: www.GHCA.info.
Contact:
Kayla Lounsbery
Sr. Marketing Manager
National Research Corporation
800-388-4264
[email protected]



Read more...

Ratios

vs
industry
vs
history
PE Ratio 14.56
NRCIB's PE Ratio is ranked higher than
87% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. NRCIB: 14.56 )
Ranked among companies with meaningful PE Ratio only.
NRCIB' s PE Ratio Range Over the Past 10 Years
Min: 2.19  Med: 3.84 Max: 18.88
Current: 14.56
2.19
18.88
PE Ratio without NRI 14.56
NRCIB's PE Ratio without NRI is ranked higher than
87% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. NRCIB: 14.56 )
Ranked among companies with meaningful PE Ratio without NRI only.
NRCIB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.19  Med: 3.84 Max: 18.88
Current: 14.56
2.19
18.88
Price-to-Owner-Earnings 13.03
NRCIB's Price-to-Owner-Earnings is ranked higher than
91% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. NRCIB: 13.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NRCIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.42  Med: 3.35 Max: 20.92
Current: 13.03
1.42
20.92
PB Ratio 12.25
NRCIB's PB Ratio is ranked lower than
89% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. NRCIB: 12.25 )
Ranked among companies with meaningful PB Ratio only.
NRCIB' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 0.71 Max: 16.24
Current: 12.25
0.42
16.24
PS Ratio 2.68
NRCIB's PS Ratio is ranked higher than
63% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. NRCIB: 2.68 )
Ranked among companies with meaningful PS Ratio only.
NRCIB' s PS Ratio Range Over the Past 10 Years
Min: 0.32  Med: 0.59 Max: 3.3
Current: 2.68
0.32
3.3
Price-to-Free-Cash-Flow 12.81
NRCIB's Price-to-Free-Cash-Flow is ranked higher than
83% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. NRCIB: 12.81 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NRCIB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.44  Med: 3.21 Max: 16.3
Current: 12.81
1.44
16.3
Price-to-Operating-Cash-Flow 10.92
NRCIB's Price-to-Operating-Cash-Flow is ranked higher than
78% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. NRCIB: 10.92 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NRCIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.23  Med: 2.77 Max: 14.48
Current: 10.92
1.23
14.48
EV-to-EBIT 16.54
NRCIB's EV-to-EBIT is ranked higher than
70% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. NRCIB: 16.54 )
Ranked among companies with meaningful EV-to-EBIT only.
NRCIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.5  Med: 2.9 Max: 12.3
Current: 16.54
1.5
12.3
EV-to-EBITDA 14.58
NRCIB's EV-to-EBITDA is ranked higher than
63% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. NRCIB: 14.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
NRCIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.2  Med: 2.3 Max: 10.6
Current: 14.58
1.2
10.6
Shiller PE Ratio 13.90
NRCIB's Shiller PE Ratio is ranked higher than
93% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. NRCIB: 13.90 )
Ranked among companies with meaningful Shiller PE Ratio only.
NRCIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.47  Med: 6.64 Max: 16.45
Current: 13.9
3.47
16.45
Current Ratio 1.49
NRCIB's Current Ratio is ranked lower than
76% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. NRCIB: 1.49 )
Ranked among companies with meaningful Current Ratio only.
NRCIB' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.53 Max: 5.21
Current: 1.49
0.49
5.21
Quick Ratio 1.49
NRCIB's Quick Ratio is ranked lower than
68% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. NRCIB: 1.49 )
Ranked among companies with meaningful Quick Ratio only.
NRCIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.53 Max: 5.21
Current: 1.49
0.49
5.21
Days Sales Outstanding 36.25
NRCIB's Days Sales Outstanding is ranked higher than
83% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. NRCIB: 36.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
NRCIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.97  Med: 45.13 Max: 57.87
Current: 36.25
29.97
57.87
Days Payable 6.13
NRCIB's Days Payable is ranked lower than
92% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. NRCIB: 6.13 )
Ranked among companies with meaningful Days Payable only.
NRCIB' s Days Payable Range Over the Past 10 Years
Min: 3  Med: 8.15 Max: 184.63
Current: 6.13
3
184.63

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.20
NRCIB's Dividend Yield % is ranked higher than
94% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. NRCIB: 5.20 )
Ranked among companies with meaningful Dividend Yield % only.
NRCIB' s Dividend Yield % Range Over the Past 10 Years
Min: 0.94  Med: 12.7 Max: 23.19
Current: 5.2
0.94
23.19
Dividend Payout Ratio 0.70
NRCIB's Dividend Payout Ratio is ranked higher than
90% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. NRCIB: 0.70 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NRCIB' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.51 Max: 0.7
Current: 0.7
0.14
0.7
3-Year Dividend Growth Rate 48.70
NRCIB's 3-Year Dividend Growth Rate is ranked higher than
83% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.60 vs. NRCIB: 48.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NRCIB' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 48.7
Current: 48.7
0
48.7
Forward Dividend Yield % 5.78
NRCIB's Forward Dividend Yield % is ranked higher than
95% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. NRCIB: 5.78 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.72
NRCIB's 5-Year Yield-on-Cost % is ranked higher than
84% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. NRCIB: 4.72 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NRCIB' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.85  Med: 11.55 Max: 21.07
Current: 4.72
0.85
21.07
3-Year Average Share Buyback Ratio -0.30
NRCIB's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. NRCIB: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NRCIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -93.8  Med: 0 Max: 0
Current: -0.3
-93.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 109.21
NRCIB's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. NRCIB: 109.21 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NRCIB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.39  Med: 1.51 Max: 716.4
Current: 109.21
0.39
716.4
Price-to-Tangible-Book 46.47
NRCIB's Price-to-Tangible-Book is ranked lower than
96% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. NRCIB: 46.47 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NRCIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.25  Med: 0.75 Max: 90.16
Current: 46.47
0.25
90.16
Price-to-Intrinsic-Value-Projected-FCF 1.18
NRCIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. NRCIB: 1.18 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NRCIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.12  Med: 0.23 Max: 1.22
Current: 1.18
0.12
1.22
Price-to-Median-PS-Value 4.53
NRCIB's Price-to-Median-PS-Value is ranked lower than
98% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. NRCIB: 4.53 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NRCIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 0.9 Max: 4.55
Current: 4.53
0.37
4.55
Price-to-Graham-Number 5.43
NRCIB's Price-to-Graham-Number is ranked lower than
80% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. NRCIB: 5.43 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NRCIB' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.13  Med: 0.37 Max: 7.94
Current: 5.43
0.13
7.94
Earnings Yield (Greenblatt) % 6.05
NRCIB's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. NRCIB: 6.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NRCIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 8.1  Med: 34.7 Max: 68.2
Current: 6.05
8.1
68.2
Forward Rate of Return (Yacktman) % -3.03
NRCIB's Forward Rate of Return (Yacktman) % is ranked lower than
78% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. NRCIB: -3.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NRCIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.1  Med: 38 Max: 65
Current: -3.03
-3.1
65

More Statistics

Revenue (TTM) (Mil) $109.4
EPS (TTM) $ 2.85
Beta-0.05
Short Percentage of Float0.86%
52-Week Range $32.18 - 46.37
Shares Outstanding (Mil)24.45

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.93
EPS without NRI ($) 0.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.00%
Dividends per Share ($)
» More Articles for NRCIB

Headlines

Articles On GuruFocus.com
National Research Corporation to Broadcast its 2017 First Quarter Conference Call Live on the Intern Apr 17 2017 
Backtesting Feature Identifies Top-Performing Strategies Aug 31 2016 
National Research Corporation Declares Quarterly Dividend May 12 2016 
Report: Georgia Nursing Homes Praised by Consumers May 10 2016 
NRC Transparency Solution Passes New Milestone in Pursuit of Customer-Centric Health Apr 07 2016 
Unite Private Networks Provides High-Speed Internet Capabilities for National Research Corporation Apr 05 2016 
Meridian Funds Comments on National Research Corp Jun 20 2014 
My 4 Favorite Stocks From The Undervalued Predictable Screener Oct 11 2013 
Four Predictable, Undervalued Stocks Held by Billionaire Investors Sep 22 2013 
13 Not Expensive Stocks with Dividend Yields Over 3% as Well as a Consistent Business Sep 10 2013 

More From Other Websites
National Research Corporation to Broadcast its 2017 First Quarter Conference Call Live on the... Apr 17 2017
Georgia Skilled Nursing Care Centers Receive Praise Year after Year Apr 12 2017
National Research Corporation Canada Announces New Brand Identity: NRC Health Apr 05 2017
Here's Why You Should Bet on TransUnion (TRU) Stock Now Mar 24 2017
National Research Corp. :NRCIB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Mar 16 2017
Verisk (VRSK) Poised for Long-Term Growth Despite Risks Mar 13 2017
National Research Corp. :NRCIB-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017 Mar 10 2017
Should You Get Rid of Dun & Bradstreet Corp. (DNB) Now? Feb 23 2017
National Research Corporation Announces Fourth Quarter and Year-End 2016 Results Feb 14 2017
National Research Corporation to Broadcast its 2016 Fourth Quarter and Year-End Conference Call Live... Feb 03 2017
National Research Corporation, Now NRC Health, Launches Real-time Feedback Solution Alongside New... Dec 05 2016
Edited Transcript of NRCIB earnings conference call or presentation 2-Nov-16 3:00pm GMT Nov 21 2016
National Research Corporation Announces 21st Annual Consumer Choice Award Winners and Advent of New... Nov 07 2016
National Research Corp. :NRCIB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016 Nov 03 2016
Impressive Profit Growth At National Research Nov 02 2016
Inova and National Research Corporation Take Podium at 20th Annual Healthcare Internet Conference Oct 31 2016
Business Information Q3 Earnings on Nov 1: VRSK, DNB & More Oct 31 2016
Verisk's Affiliate Expands Product Portfolio to Boost Sales Oct 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)